Dried-Plasma Transport Using a Novel Matrix and Collection System for Human Immunodeficiency Virus and Hepatitis C Virus Virologic Testing
R. M. Lloyd,D. A. Burns,J. T. Huong,R. L. Mathis,M. A. Winters,M. Tanner,A. De La Rosa,B. Yen-Lieberman,W. Armstrong,A. Taege,D. R. McClernon,J. L. Wetshtein,Brian M. Friedrich,Monique R. Ferguson,William O'Brien,P. M. Feorino,M. Holodniy
DOI: https://doi.org/10.1128/jcm.02354-08
2009-05-01
Journal of Clinical Microbiology
Abstract:ABSTRACT A novel method for the collection and transportation of dried-blood-plasma samples, SampleTanker (ST), was developed and compared to standard shipping protocols for frozen-plasma specimens containing human immunodeficiency virus type 1 (HIV-1) and/or hepatitis C virus (HCV). Matched frozen and dried 1-ml EDTA-containing plasma samples were collected and analyzed by several molecular-based virologic assays. After addition of 1.175 ml of reconstitution buffer, 1.035 ml of dried plasma was recovered. Mean intra-assay variances were 0.05, 0.05, and 0.06 log 10 copies/ml for the Versant, Amplicor, and NucliSens QT HIV-1 load assays, respectively ( P , not significant). However, mean HIV-1 viral load was consistently reduced in dried samples by 0.32 to 0.51 log 10 copies/ml, depending on assay type ( P 99% concordant at the nucleotide and amino acid levels, as well as for resistance-associated mutations. We further demonstrated successful detection of multiple analytes, including HIV-1 viral load, HIV-1 antiretroviral resistance genotype, and HCV genotype, from a single ST unit. Dried plasma collected with ST yielded comparable results to frozen samples for multiple-analyte clinical testing. As such, ST could be a useful alternative for virologic tests and clinical trials worldwide by significantly diminishing transportation cost and the sample volume restrictions associated with dried-blood-spot technology.
microbiology